BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 167 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Formula:C17H19N3O2Purity:99.77%Color and Shape:SolidMolecular weight:297.36Ref: TM-T39130
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)356.00€25mg573.00€50mg879.00€100mg1,314.00€GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFormula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Color and Shape:Odour Liquid(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Formula:C11H8Br2N2O2Purity:99.88%Color and Shape:SolidMolecular weight:360Fenebrutinib
CAS:Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
Formula:C37H44N8O4Purity:98.26% - 98.94%Color and Shape:SolidMolecular weight:664.8PCI 29732
CAS:PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.Formula:C22H21N5OPurity:99.81%Color and Shape:SolidMolecular weight:371.43CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Formula:C34H37N5O4Purity:97.69% - 97.88%Color and Shape:SolidMolecular weight:579.69BIIB068
CAS:BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.Formula:C23H29N7O2Purity:97.98%Color and Shape:SolidMolecular weight:435.52Ref: TM-T9192
1mg46.00€5mg90.00€1mL*10mM (DMSO)100.00€10mg152.00€25mg264.00€50mg398.00€100mg532.00€200mg705.00€BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Formula:C32H30F2N4O4Purity:99.44% - 99.76%Color and Shape:SolidMolecular weight:572.6Ref: TM-T5138
1mg105.00€2mg165.00€5mg289.00€1mL*10mM (DMSO)358.00€10mg447.00€25mg715.00€50mg964.00€100mg1,243.00€200mg1,693.00€CHMFL-BMX-078
CAS:CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.Formula:C33H35N7O6Purity:>99.99%Color and Shape:SolidMolecular weight:625.67N-piperidine Ibrutinib
CAS:N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively.Formula:C22H22N6OPurity:96.65%Color and Shape:SolidMolecular weight:386.45Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Formula:C29H29ClN6O4Purity:99.22%Color and Shape:SolidMolecular weight:561.03Ref: TM-T9072
2mg38.00€5mg57.00€1mL*10mM (DMSO)71.00€10mg90.00€25mg178.00€50mg334.00€100mg497.00€200mg712.00€(Rac)-IBT6A
CAS:(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.24%Color and Shape:SolidMolecular weight:386.45Ref: TM-T10626
1mg44.00€2mg57.00€1mL*10mM (DMSO)92.00€5mg93.00€10mg120.00€25mg215.00€50mg313.00€100mg439.00€200mg628.00€zanubrutinib
CAS:Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purity:98.42% - 99.76%Color and Shape:SolidMolecular weight:471.55Ref: TM-T7584
1mg59.00€5mg137.00€1mL*10mM (DMSO)142.00€10mg236.00€25mg492.00€50mg737.00€100mg1,018.00€Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Formula:C17H13N5OPurity:99.47%Color and Shape:SolidMolecular weight:303.32TL-895
CAS:TL-895 is a potent, selective ATP-competitive BTK inhibitor (IC50 = 1.5 nM, Ki = 11.9 nM).Formula:C25H26FN5O2Purity:99.96%Color and Shape:SolidMolecular weight:447.5Ref: TM-T9705
2mg39.00€5mg60.00€1mL*10mM (DMSO)60.00€10mg87.00€25mg172.00€50mg266.00€100mg391.00€200mg555.00€Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFormula:C26H36ClFN4O11S2Color and Shape:SolidMolecular weight:699.17ONO-4059 analog
CAS:ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.Formula:C25H24N6O3Purity:99.25%Color and Shape:SolidMolecular weight:456.5Ref: TM-T6921
1mg43.00€2mg56.00€1mL*10mM (DMSO)90.00€5mg93.00€10mg137.00€25mg264.00€50mg439.00€100mg627.00€Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Formula:C26H26N6O2SPurity:99.14% - 99.63%Color and Shape:SolidMolecular weight:486.59Ref: TM-T6918
2mg37.00€5mg54.00€1mL*10mM (DMSO)56.00€10mg84.00€25mg130.00€50mg170.00€100mg268.00€200mg437.00€CNX-774
CAS:CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).Formula:C26H22FN7O3Purity:97.35% - 99.11%Color and Shape:SolidMolecular weight:499.5Ref: TM-T2302
1mg38.00€2mg50.00€5mg84.00€1mL*10mM (DMSO)88.00€10mg119.00€25mg222.00€50mg369.00€100mg537.00€500mg1,161.00€RN486
CAS:RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).Formula:C35H35FN6O3Purity:99.38%Color and Shape:SolidMolecular weight:606.69Remibrutinib
CAS:Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood.Formula:C27H27F2N5O3Purity:99.5% - 99.81%Color and Shape:SolidMolecular weight:507.53Ref: TM-T16730
1mg92.00€5mg210.00€1mL*10mM (DMSO)235.00€10mg340.00€25mg572.00€50mg713.00€100mg1,099.00€200mg1,485.00€(S)-Sunvozertinib
CAS:(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor.Formula:C29H35ClFN7O3Purity:99.64%Color and Shape:SolidMolecular weight:584.08Branebrutinib
CAS:Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family.Formula:C20H23FN4O2Purity:95.86% - 99.31%Color and Shape:SolidMolecular weight:370.42Spebrutinib
CAS:Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplasticFormula:C22H22FN5O3Purity:97.02% - >99.99%Color and Shape:SolidMolecular weight:423.44Acalabrutinib
CAS:Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.Formula:C26H23N7O2Purity:98.94% - 99.64%Color and Shape:SolidMolecular weight:465.51Ref: TM-T3626
5mg44.00€1mL*10mM (DMSO)48.00€10mg57.00€25mg78.00€50mg90.00€100mg144.00€200mg215.00€500mg355.00€Ibrutinib
CAS:Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.Formula:C25H24N6O2Purity:98% - 99.95%Color and Shape:SolidMolecular weight:440.50BTK IN-1
CAS:BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
Formula:C19H21ClN6OPurity:97.38%Color and Shape:SolidMolecular weight:384.86Avitinib
CAS:Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor,Formula:C26H26FN7O2Purity:99.81% - >99.99%Color and Shape:SolidMolecular weight:487.53Tolebrutinib
CAS:Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.Formula:C26H25N5O3Purity:98.4% - 98.82%Color and Shape:SolidMolecular weight:455.51Ref: TM-T9125
2mg40.00€5mg71.00€1mL*10mM (DMSO)80.00€10mg105.00€25mg177.00€50mg264.00€100mg434.00€200mg622.00€BTK Protein, Human, Recombinant (His)
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.Purity:90%Color and Shape:Lyophilized PowderMolecular weight:78.3 kDa (predicted)Ibrutinib-d5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:445.53CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Formula:C20H24BrF2N5O3SPurity:99.14%Color and Shape:SolidMolecular weight:532.4JNJ-64264681
CAS:JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Formula:C27H30N6O3SPurity:98%Color and Shape:SolidMolecular weight:518.63BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Formula:C25H23N5O3Purity:98%Color and Shape:SolidMolecular weight:441.48SJF620
CAS:SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).Formula:C41H44N8O7Purity:98%Color and Shape:SolidMolecular weight:760.84PF-06658607
CAS:PF-06658607 is an alkynylated irreversible Brutons tyrosine kinase (BTK) inhibitor.Formula:C27H24N6O2Color and Shape:SolidMolecular weight:464.52PF-06465469
CAS:PF-06465469, a covalent ITK and BTK inhibitor (IC₅₀ = 2 nM), suppresses CXCL12-mediated migration and decreases PD-1/LAG-3 for leukemia and lymphoma research.Formula:C30H33N7O2Purity:98%Color and Shape:SolidMolecular weight:523.63VA5 TG2 inhibitor
CAS:VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.Formula:C31H34N4O8Purity:98%Color and Shape:SolidMolecular weight:590.62ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Formula:C26H23N7O3Color and Shape:SolidMolecular weight:481.51CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formula:C29H27N5OColor and Shape:SolidMolecular weight:461.56BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purity:99.05%Color and Shape:SolidMolecular weight:297.35Ref: TM-T72653
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)462.00€25mg573.00€50mg879.00€100mg1,314.00€JAK3/BTK-IN-6
CAS:JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2CHMFL-BTK-01
CAS:CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.Formula:C38H41N5O5Purity:98%Color and Shape:SolidMolecular weight:647.76BI-1622
CAS:BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53EGFR-IN-40
CAS:EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).Formula:C23H20N6O3Color and Shape:SolidMolecular weight:428.44Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formula:C32H39N9O2Color and Shape:SolidMolecular weight:581.71
